Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34119634)
Watch
English
Pemetrexed disodium, a novel antifolate with multiple targets
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
review article
1 reference
stated in
Europe PubMed Central
title
Pemetrexed disodium, a novel antifolate with multiple targets
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
author name string
N J Curtin
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
A N Hughes
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
publication date
1 May 2001
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
volume
2
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
page(s)
298-306
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
issue
5
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
cites work
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Folate-based thymidylate synthase inhibitors as anticancer drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Glutamyl hydrolase and the multitargeted antifolate LY231514.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thymidine concentrations in serum and urine of different animal species and man
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(00)00325-9
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
PubMed ID
11905785
1 reference
stated in
Europe PubMed Central
PubMed ID
11905785
retrieved
31 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit